CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.
Curr Res Transl Med
; 68(3): 111-118, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-622221
ABSTRACT
The pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly across the world. Currently, the COVID-19 pandemic is affecting the continuity of essential routine healthcare services and procedures, including chimeric antigen receptor T-cell (CAR-T) therapy, a life-saving option for patients with relapsed/refractory (R/R) hematologic malignancies. Due to the rapid disease progression of hematological malignancies, there is an urgent need to manufacture and utilize CAR T-cells. However, CAR-T treatment has become extraordinarily challenging during this COVID-19 pandemic. Thus, many medical and technical factors must now be taken into consideration before, during, and after CAR-T therapy. The purpose of this review is to provide brief suggestions for rational decision-making strategies in evaluating and selecting CAR T-cell treatment and appropriate CAR T-cell products, and protective strategies for medical staff and patients to prevent infection in the midst of the current COVID-19 pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Receptors, Antigen, T-Cell
/
Immunotherapy, Adoptive
/
Infection Control
/
Coronavirus Infections
/
Hematologic Neoplasms
/
Delivery of Health Care
/
Pandemics
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Variants
Limits:
Humans
Language:
English
Journal:
Curr Res Transl Med
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS